公开(公告)号：US20230172172A1

公开(公告)日：2023-06-08

申请号：US18159414

申请日：2023-01-25

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew J. Murphy ,  Alexander O. Mujica ,  Ka-Man Venus Lai ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan

IPC: A01K67/027 ,  C07K16/24 ,  C07K16/28 ,  C12N15/85

CPC classification number: A01K67/0278 ,  C07K16/244 ,  C07K16/2866 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2015/8527 ,  A01K2267/0368 ,  A01K2217/15

Abstract: This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.

公开(公告)号：US11666666B2

公开(公告)日：2023-06-06

申请号：US16076616

申请日：2017-02-09

Applicant: The Regents of the University of California

Inventor： April D. Pyle ,  Courtney S. Young ,  Melissa J. Spencer

IPC: A61K48/00 ,  C07K14/47 ,  C12N15/90 ,  C12N15/113 ,  A61P21/00 ,  C12N5/074 ,  C12N15/861

CPC classification number: A61K48/0066 ,  A61K48/0091 ,  A61P21/00 ,  C07K14/4708 ,  C12N5/0696 ,  C12N15/113 ,  C12N15/907 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0306 ,  C12N15/861 ,  C12N2310/20

Abstract: The present disclosure provides a method of modifying a mutant dystrophin gene in the genome of a cell. The present disclosure further provides compositions and kits for modifying a mutant dystrophin gene in the genome of a cell.

公开(公告)号：US20230165901A1

公开(公告)日：2023-06-01

申请号：US17901424

申请日：2022-09-01

Applicant: Mesoblast, Inc.

Inventor： Piroska Elizabeth Rakoczy

IPC: A61K35/28 ,  A01K67/027 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A01K67/027 ,  C12N5/0663 ,  A01K2207/30 ,  A01K2227/105 ,  A01K2267/0375 ,  A01K2267/0393 ,  A61K2035/124

Abstract: The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.

公开(公告)号：US20190240327A9

公开(公告)日：2019-08-08

申请号：US14075566

申请日：2013-11-08

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Hong Yu ,  Drew M. Pardoll ,  Xiaoyu Pan ,  Charles G. Drake ,  Jonathan D. Powell ,  Ching-Tai Huang ,  Joseph Barbi ,  Fan Pan

IPC: A61K39/395 ,  A61K35/14 ,  A61K31/713 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/052 ,  A01K2217/075 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K31/713 ,  A61K35/17 ,  A61K38/18 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/475 ,  C07K16/22 ,  C07K2319/30

Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.

公开(公告)号：US20190233496A1

公开(公告)日：2019-08-01

申请号：US16121297

申请日：2018-09-04

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL

IPC: C07K14/725 ,  C07K14/715 ,  C12N5/00 ,  A61P25/28 ,  C07K14/47 ,  C07K16/18 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K14/7051 ,  A01K2227/105 ,  A01K2267/0312 ,  A61K35/15 ,  A61K38/00 ,  A61K39/0007 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61P25/28 ,  C07K14/4711 ,  C07K14/70517 ,  C07K14/7153 ,  C07K16/18 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/00 ,  C12N2740/16043

Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent a neurological disease, disorder, or injury.

公开(公告)号：US20190208754A1

公开(公告)日：2019-07-11

申请号：US16355707

申请日：2019-03-16

Applicant: Zhejiang University

Inventor： Jun Li ,  Suwan Sun ,  Jiang Li ,  Jing Jiang

IPC: A01K67/027 ,  A61K9/00 ,  C12N5/0735

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2207/20 ,  A01K2227/105 ,  A01K2227/106 ,  A01K2267/0337 ,  A61K9/0019 ,  A61K9/0053 ,  C12N5/0606

Abstract: A method of constructing humanized murine model using stem cells, includes obtaining human stem cells; transplanting human stem cells into murine with liver damage; and obtaining hepatotropic virus infected humanized murine. It was found that by inducing severe liver damage and transplanting human stem cells, human-derived hepatocytes in murine liver have a high chimeric rate of 50-95%, and human-derived immune cells may exist in murine organs such as spleen, blood, liver, and bone marrow, thereby forming murine model of humanized liver and immune cell. The humanized murines are then infected with various types of hepatotropic viruses to form humanized hepatotropic viral infected murine model. In addition to construction of model for studying hepatotropic viral infection using the technique for constructing the humanized murine model, the concept of this technical solution may also be used for constructing models of other humanized organs.

公开(公告)号：US20190208753A1

公开(公告)日：2019-07-11

申请号：US16353870

申请日：2019-03-14

Applicant: Kymab Limited

Inventor： Jasper Clube

IPC: A01K67/027 ,  C07K16/46 ,  C12N15/85 ,  C07K16/00

CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/461 ,  C07K16/462 ,  C07K2317/92 ,  C12N15/8509

Abstract: The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo. Using the present invention it is possible straightforwardly and rapidly to obtain antigen-specific antibodies that are fully human (ie, comprising human variable and constant regions) and have undergone recombination, junctional diversification, affinity maturation and isotype switching in vivo in a non-human vertebrate system. Furthermore, such antibodies are humanised (eg, totally human)—and selected—totally in vivo, and as such the present invention harnesses in vivo filtering for expressibility, affinity and biophysical characteristics in the context of the desired human variable and constant region pairings. This is avoids problems of down-grading antibody characteristics when humanising the constant region of chimaeric antibodies in vitro.

公开(公告)号：US20190192572A1

公开(公告)日：2019-06-27

申请号：US16322812

申请日：2017-08-02

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Baochun Zhang ,  IL-Kyu Choi ,  Zhe Wang

IPC: A61K35/17 ,  A01K67/027 ,  C12N15/62 ,  C12N15/85 ,  A61K35/768 ,  A61P35/00 ,  C07K14/005

CPC classification number: A61K35/17 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K35/768 ,  A61K45/06 ,  A61P35/00 ,  C07K14/005 ,  C12N15/62 ,  C12N15/85 ,  C12N2710/16222 ,  C12N2740/10043

Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.

公开(公告)号：US20190054121A1

公开(公告)日：2019-02-21

申请号：US16155801

申请日：2018-10-09

Applicant: Fred Hutchinson Cancer Research Center

Inventor： Matthias Stephan

IPC: A61K35/17 ,  C12N5/09 ,  A01K67/027 ,  C07K16/28 ,  A61K9/14 ,  A61K39/44 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K35/17 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K9/0024 ,  A61K9/146 ,  A61K39/44 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2878 ,  C12N5/0694 ,  C12N2510/00 ,  C12N2533/54 ,  C12N2533/74

Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

公开(公告)号：US20180355028A1

公开(公告)日：2018-12-13

申请号：US15981008

申请日：2018-05-16

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Tamie J. Chilcote ,  Jason Goldstein ,  John P. Anderson ,  Donald Walker

IPC: C07K16/18 ,  G01N33/68 ,  C12Q1/6883 ,  C12N15/85

CPC classification number: C07K16/18 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2227/706 ,  A01K2267/0356 ,  A61K38/00 ,  C07K2317/33 ,  C07K2317/34 ,  C12N15/8509 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/2835

Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.